Avancerad sökning
Visar resultat 1 - 5 av 8 avhandlingar som matchar ovanstående sökkriterier.
1. Searching for Synergy : Radiosensitization of 177Lu-DOTATATE
Sammanfattning : Cancers presents a major health challenge, and there is a pressing need to develop new therapeutic strategies. Surgery, chemotherapy and radiation are the most commonly used treatments for cancer today. Radiation can be given as targeted radionuclide therapy (TRT), i.e. LÄS MER
2. Towards Personalized Cancer Therapy : New Diagnostic Biomarkers and Radiosensitization Strategies
Sammanfattning : This thesis focuses on the evaluation of biomarkers for radio-immunodiagnostics and radio-immunotherapy and on radiosensitization strategies after HSP90 inhibition, as a step towards more personalized cancer medicine. There is a need to develop new tracers that target cancer-specific biomarkers to improve diagnostic imaging, as well as to combine treatment strategies to potentiate synergistic effects. LÄS MER
3. Targeted radiotherapy in metastatic neuroendocrine tumours: clinical and experimental studies
Sammanfattning : ABSTRACT Neuroendocrine tumours (NET) often present at a metastatic stage, which diminishes the possibility for curative surgery. Peptide receptor radiotherapy (PRRT) with 177Lu-DOTATATE targets somatostatin receptors, which are overexpressed on NET cells. PRRT results in symptom relief and often tumour control of NETs, but rarely cure. LÄS MER
4. ARCON in experimental and clinical radiotherapy
Sammanfattning : xHypoxia and repopulation of tumour clonogens are two important determinants of treatment outcome in radiotherapy. In general clinical evidence indicates that loco-regional control may be reduced with long overall treatment times and for tumours with low pre-treatment levels of oxygen. LÄS MER
5. Precision medicine and targeted therapy : Turning the tables on cancer
Sammanfattning : An extended understanding of the molecular characteristics of cancer has led to a revolution within the field of precision medicine. This thesis explores the utilization of two targets for precision medicine, namely, CD44v6 and murine double-minute 2 and X (MDM2/X). LÄS MER